+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CAR T Cell"

From
From
CAR T-cell Therapy Market 2025-2029 - Product Thumbnail Image

CAR T-cell Therapy Market 2025-2029

  • Report
  • January 2025
  • 199 Pages
  • Global
From
From
From
From
From
Innovation Insights: B-cell Depletion - Product Thumbnail Image

Innovation Insights: B-cell Depletion

  • Report
  • December 2024
  • 55 Pages
  • Global
From
Cancer Immunotherapy - A Global Market Overview - Product Thumbnail Image

Cancer Immunotherapy - A Global Market Overview

  • Report
  • November 2024
  • 256 Pages
  • Global
From
Immuno-Oncology Clinical Trials Market Report 2023-2033 - Product Thumbnail Image

Immuno-Oncology Clinical Trials Market Report 2023-2033

  • Report
  • September 2023
  • 249 Pages
  • Global
From
From
Loading Indicator

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells. CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors. CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more